Limits...
Estrogenicity of glabridin in Ishikawa cells.

Su Wei Poh M, Voon Chen Yong P, Viseswaran N, Chia YY - PLoS ONE (2015)

Bottom Line: Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT).However, glabridin also induced an increase in cell proliferation.When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone.

View Article: PubMed Central - PubMed

Affiliation: School of Biosciences, Division of Medicine, Pharmacy and Health Sciences, Taylor's University, No. 1, Jln Taylor's, 47500 Subang Jaya, Malaysia.

ABSTRACT
Glabridin is an isoflavan from licorice root, which is a common component of herbal remedies used for treatment of menopausal symptoms. Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT). This study aims to evaluate the estrogenic effect of glabridin in an in-vitro endometrial cell line -Ishikawa cells via alkaline phosphatase (ALP) assay and ER-α-SRC-1-co-activator assay. Its effect on cell proliferation was also evaluated using Thiazoyl blue tetrazolium bromide (MTT) assay. The results showed that glabridin activated the ER-α-SRC-1-co-activator complex and displayed a dose-dependent increase in estrogenic activity supporting its use as an ERT. However, glabridin also induced an increase in cell proliferation. When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone. This suggest that the combination might be better suited for providing high estrogenic effects with lower incidences of endometrial cancer that is associated with 17β-E2.

No MeSH data available.


Related in: MedlinePlus

Effect of varying concentrations of glabridin with 1nM 17β-E2 on the induction of cell proliferation in Ishikawa cells in comparison to 1nM 17β-E2.There was no significant difference between the combination treatments with 1nM 17β-E2.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4376725&req=5

pone.0121382.g007: Effect of varying concentrations of glabridin with 1nM 17β-E2 on the induction of cell proliferation in Ishikawa cells in comparison to 1nM 17β-E2.There was no significant difference between the combination treatments with 1nM 17β-E2.

Mentions: A look at the effect of glabridin against a background of 1nM 17β-E2 showed that there was no significant increase in cell proliferation as compared to 1nM 17β-E2 (Fig. 7). In the past, Tamir et al. [6] showed that glabridin did not have much effect on the cell proliferative effect of 17β-E2 in breast cancer cells. Likewise, this study observed that glabridin (100pM to 10μM) had little influence on the effect of 17β-E2 on cell proliferation in Ishikawa cells with a maximal difference of less than 20% with the addition of glabridin at certain concentrations. However, there was still a slight decrease in cell proliferation in the combination treatment of 100nM glabridin with 1nM 17β-E2 (16.98 ± 3.76% increase from control) compared (19.67 ± 3.42% increase) to 1nM 17β-E2, though not significant. Meanwhile, the combination did show a significant decrease in cell proliferation from that of 10nM 17β-E2 (28.79 ± 1.26% increase). Both the ALP and RCAS assay showed that 100nM glabridin with 1nM 17β-E2 significantly increased ALP and ER-α-SRC-1-co-activator activity compared to 1nM 17β-E2 but a decrease in induction of cell proliferation was observed compared to treatment with 1nM 17β-E2 only. It is unknown why there was a decrease, but perhaps ER-α-independent actions might be involved.


Estrogenicity of glabridin in Ishikawa cells.

Su Wei Poh M, Voon Chen Yong P, Viseswaran N, Chia YY - PLoS ONE (2015)

Effect of varying concentrations of glabridin with 1nM 17β-E2 on the induction of cell proliferation in Ishikawa cells in comparison to 1nM 17β-E2.There was no significant difference between the combination treatments with 1nM 17β-E2.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4376725&req=5

pone.0121382.g007: Effect of varying concentrations of glabridin with 1nM 17β-E2 on the induction of cell proliferation in Ishikawa cells in comparison to 1nM 17β-E2.There was no significant difference between the combination treatments with 1nM 17β-E2.
Mentions: A look at the effect of glabridin against a background of 1nM 17β-E2 showed that there was no significant increase in cell proliferation as compared to 1nM 17β-E2 (Fig. 7). In the past, Tamir et al. [6] showed that glabridin did not have much effect on the cell proliferative effect of 17β-E2 in breast cancer cells. Likewise, this study observed that glabridin (100pM to 10μM) had little influence on the effect of 17β-E2 on cell proliferation in Ishikawa cells with a maximal difference of less than 20% with the addition of glabridin at certain concentrations. However, there was still a slight decrease in cell proliferation in the combination treatment of 100nM glabridin with 1nM 17β-E2 (16.98 ± 3.76% increase from control) compared (19.67 ± 3.42% increase) to 1nM 17β-E2, though not significant. Meanwhile, the combination did show a significant decrease in cell proliferation from that of 10nM 17β-E2 (28.79 ± 1.26% increase). Both the ALP and RCAS assay showed that 100nM glabridin with 1nM 17β-E2 significantly increased ALP and ER-α-SRC-1-co-activator activity compared to 1nM 17β-E2 but a decrease in induction of cell proliferation was observed compared to treatment with 1nM 17β-E2 only. It is unknown why there was a decrease, but perhaps ER-α-independent actions might be involved.

Bottom Line: Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT).However, glabridin also induced an increase in cell proliferation.When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone.

View Article: PubMed Central - PubMed

Affiliation: School of Biosciences, Division of Medicine, Pharmacy and Health Sciences, Taylor's University, No. 1, Jln Taylor's, 47500 Subang Jaya, Malaysia.

ABSTRACT
Glabridin is an isoflavan from licorice root, which is a common component of herbal remedies used for treatment of menopausal symptoms. Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT). This study aims to evaluate the estrogenic effect of glabridin in an in-vitro endometrial cell line -Ishikawa cells via alkaline phosphatase (ALP) assay and ER-α-SRC-1-co-activator assay. Its effect on cell proliferation was also evaluated using Thiazoyl blue tetrazolium bromide (MTT) assay. The results showed that glabridin activated the ER-α-SRC-1-co-activator complex and displayed a dose-dependent increase in estrogenic activity supporting its use as an ERT. However, glabridin also induced an increase in cell proliferation. When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone. This suggest that the combination might be better suited for providing high estrogenic effects with lower incidences of endometrial cancer that is associated with 17β-E2.

No MeSH data available.


Related in: MedlinePlus